...
首页> 外文期刊>Allergy >Effectiveness of omalizumab in monozygotic twin sisters with severe allergic asthma.
【24h】

Effectiveness of omalizumab in monozygotic twin sisters with severe allergic asthma.

机译:奥马珠单抗在患有严重过敏性哮喘的单卵双胞胎姐妹中的有效性。

获取原文
获取原文并翻译 | 示例
           

摘要

Between 5% and 10% of children worldwide suffer from asthma (1). The familial nature of asthma is well known; the risk for a first cousin of an asthmatic patient is multiplied by 2.5-3 compared with the general population (2). Studies of twins have confirmed this genetic component finding higher concordance of asthma among monozygotic (58.97%) than dizygotic twins (23.64%) (3). We report an exceptional clinical situation of monozygotic twin sisters with severe allergic asthma where one was treated with a monoclonal anti-IgE antibody (omalizumab), and the other with a placebo in a randomized, double-blind, placebo-controlled study (4).
机译:全球有5%至10%的儿童患有哮喘(1)。哮喘的家族性众所周知。与普通人群相比,哮喘患者首次堂兄的风险要乘以2.5-3(2)。对双胞胎的研究已经证实,这种遗传成分比单卵双胞胎(23.64%)在单卵双胎(58.97%)中发现更高的哮喘一致性(3)。在随机,双盲,安慰剂对照研究中,我们报告了患有严重过敏性哮喘的单卵双胞胎姐妹的特殊临床情况,其中一种用单克隆抗IgE抗体(奥马珠单抗)治疗,另一种用安慰剂治疗。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号